Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012
With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.
With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.